Finerenone (Kerendia, BAY94-8862): clinical trials recruiting now
4
Recruiting trials
8
Conditions studied
21
US states with sites
32
Countries
Phase breakdown
Phase 3 3
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Chronic Kidney Disease | 2 |
| Heart Failure (Pediatric) | 2 |
| Heart failure | 2 |
| Left Ventricular Systolic Dysfunction | 2 |
| Children | 1 |
| Proteinuria | 1 |
| Type 2 Diabetes Mellitus | 1 |
| Type 2 diabetes | 1 |
Recruiting trials involving Finerenone (Kerendia, BAY94-8862)
- A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
- A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
- An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
Common questions
How many recruiting trials involve Finerenone (Kerendia, BAY94-8862)?
4 recruiting trials across 8 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.